Levosimendan Zentiva

Levosimendan, the active ingredient in Levosimendan Zentiva, is a calcium sensitizer presented as a solution for injection for intravenous use. It treats acute decompensated heart failure in adult patients. GNH USA supplies Levosimendan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levosimendan acts on the cardiovascular system to improve cardiac performance in acute heart failure settings.

Acute decompensated heart failure: improves cardiac output and reduces symptoms of congestion.

Levosimendan may cause a range of adverse reactions.

Common Side Effects: - Hypotension: drop in blood pressure, especially during loading dose. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Ventricular arrhythmias: potentially life‑threatening rhythm disturbances. - Severe hypotension: marked blood pressure fall requiring intervention. - Myocardial ischemia: chest pain or ECG changes indicating reduced coronary perfusion. - Allergic reactions: rash, pruritus, or anaphylaxis.

Levosimendan requires careful monitoring and specific safety measures. - Blood pressure monitoring: observe for hypotension during and after infusion. - Cardiac rhythm surveillance: watch for arrhythmias, especially in patients with existing conduction disorders. - Renal function assessment: adjust use in severe renal impairment. - Hepatic function assessment: use cautiously in moderate to severe liver disease. - Contraindication in severe hypotension: avoid in patients with systolic BP <90 mmHg. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan may interact with several drug classes.

Major Interactions (Avoid): - Concurrent vasodilators (e.g., nitroglycerin): risk of profound hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma concentrations. - Other calcium sensitizers: additive inotropic effect can precipitate arrhythmias.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance volume depletion and hypotension. - Beta‑blockers: may blunt desired inotropic response. - ACE inhibitors or ARBs: combined effect on blood pressure requires observation.